Analysis of the VDJ rearrangement in the 12 CLL patients expressing unmutated VH genes
| Patients . | Germinal counterpart . | Homology % . | FR mutation . | RS . | CDR mutation . | RS . | CDR/FR . | D . | JH . | VL . | Homology % . | JL . | Initial stage . | Disease status . | Follow-up (mo) . |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 1-69 | 100 | 0 | 0 | 0 | 0 | 0 | D2-02 | JH6b | ND | A | PD | D(105) | ||
| 2 | 1-69 | 100 | 0 | 0 | 0 | 0 | 0 | D2-02 | JH6b | Vλ-Ig | 100 | λ1 | B | PR | D(60) |
| 3 | 1-02 | 100 | 0 | 0 | 0 | 0 | 0 | D6-19 | JH4b | O12/02 | 100 | κ3 | A | PD | D(68) |
| 4 | 1-03 | 99 | 1 | >1 | 0 | 0 | 0 | D6-19 | JH4a | Vκ-A17 | 97 | κ4 | A | PD | D(133) |
| 5 | 3-49 | 99 | 2 | >2 | 1 | >1 | 0.5 | D3-03 | JH6b | O12/02 | 98.2 | κ2 | A | PD | A(24) |
| 6 | 3-13 | 99 | 2 | 1 | 1 | >1 | 0.5 | D2-15 | JH4b | ND | B | SD | D(71) | ||
| 7 | 3-15 | 100 | 0 | 0 | 0 | 0 | 0 | D3-09 | JH4b | ND | A | PD | A(33) | ||
| 8 | 3-30.3 | 98.3 | 5 | 0.67 | 0 | 0 | 0 | D2-02 | JH4b | ND | B | PD | A(33) | ||
| 9 | 4-39 | 100 | 0 | 0 | 0 | 0 | 0 | D6-19 | JH3b | Vλ-7A | 100 | λ3b | B | PD | D(12) |
| 10 | 4-39 | 100 | 0 | 0 | 0 | 0 | 0 | D6-19 | JH6b | Vλ-3r | 100 | λ1 | C | PR | D(60) |
| 11 | 5-a | 98.3 | 3 | 0.5 | 2 | 0 | 0 | D2-15 | JH5b | ND | B | SD | A(52) | ||
| 12 | 5-51 | 99.2 | 2 | 2 | 0 | 0 | 0 | D2-21 | JH6b | L18 | 100 | κ4 | C | PR | D(52) |
| Patients . | Germinal counterpart . | Homology % . | FR mutation . | RS . | CDR mutation . | RS . | CDR/FR . | D . | JH . | VL . | Homology % . | JL . | Initial stage . | Disease status . | Follow-up (mo) . |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 1-69 | 100 | 0 | 0 | 0 | 0 | 0 | D2-02 | JH6b | ND | A | PD | D(105) | ||
| 2 | 1-69 | 100 | 0 | 0 | 0 | 0 | 0 | D2-02 | JH6b | Vλ-Ig | 100 | λ1 | B | PR | D(60) |
| 3 | 1-02 | 100 | 0 | 0 | 0 | 0 | 0 | D6-19 | JH4b | O12/02 | 100 | κ3 | A | PD | D(68) |
| 4 | 1-03 | 99 | 1 | >1 | 0 | 0 | 0 | D6-19 | JH4a | Vκ-A17 | 97 | κ4 | A | PD | D(133) |
| 5 | 3-49 | 99 | 2 | >2 | 1 | >1 | 0.5 | D3-03 | JH6b | O12/02 | 98.2 | κ2 | A | PD | A(24) |
| 6 | 3-13 | 99 | 2 | 1 | 1 | >1 | 0.5 | D2-15 | JH4b | ND | B | SD | D(71) | ||
| 7 | 3-15 | 100 | 0 | 0 | 0 | 0 | 0 | D3-09 | JH4b | ND | A | PD | A(33) | ||
| 8 | 3-30.3 | 98.3 | 5 | 0.67 | 0 | 0 | 0 | D2-02 | JH4b | ND | B | PD | A(33) | ||
| 9 | 4-39 | 100 | 0 | 0 | 0 | 0 | 0 | D6-19 | JH3b | Vλ-7A | 100 | λ3b | B | PD | D(12) |
| 10 | 4-39 | 100 | 0 | 0 | 0 | 0 | 0 | D6-19 | JH6b | Vλ-3r | 100 | λ1 | C | PR | D(60) |
| 11 | 5-a | 98.3 | 3 | 0.5 | 2 | 0 | 0 | D2-15 | JH5b | ND | B | SD | A(52) | ||
| 12 | 5-51 | 99.2 | 2 | 2 | 0 | 0 | 0 | D2-21 | JH6b | L18 | 100 | κ4 | C | PR | D(52) |
RS: replacement/silent mutation ratio; CDR/FR: CDR/FR mutation ratio; when all mutations induced replacements, results are expressed as > number of replacements observed. A (alive); D (death related to CLL); DUD (death unrelated to CLL); SD (stable disease); ND (not done). GenBank accession numbers are respectively: VH genes: U86784-U86787(cases 12, 2, 1, 3); U86799-U86801 (cases 9, 10, 4); AF196554 (case 5);AF087427 (case 6); AF087430 (case 8); AF087415 (case 11); AF087416(case 7) VL genes: U86802 (case 2); U86792 (case 3); U86806-U86808(cases 9, 10, 4); U86790 (case 12); AF228329 (case 5).